title: Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
abstract: Cerebrospinal fluid (CSF) α-synuclein (ASYN) levels are emerging as a possible biomarker in a number of neurodegenerative conditions; however, there has been little study of such levels in demyelinating conditions with neurodegeneration such as multiple sclerosis (MS). In this study, we aimed to assess CSF ASYN levels in MS spectrum [clinically isolated syndrome (CIS) and MS] patients and compare them to those obtained in control subjects with benign neurological conditions (BNC). We used a recently developed, ultra-sensitive sandwich enzyme-linked immunosorbent assay to measure and compare CSF ASYN levels in three categories of subjects: BNC (n = 38), CIS (n = 36) and MS [Relapsing Remitting (RRMS, n = 22) and Primary Progressive (PPMS, n = 15)]. We also performed secondary analyses, including relationship of CSF ASYN levels to aging, gender, presence of CSF oligoclonal bands (OB) and gadolinium (Gd)-enhancing demyelinating lesions on T1-weighted MRIs. CSF ASYN levels were found to be significantly lower in the CIS (78.2 ± 7.5 pg/mL), RRMS (76.8 ± 5.1 pg/mL), and PPMS (76.3 ± 6.7 pg/mL) groups compared to the BNC (125.7 ± 13.6 pg/mL) group. Secondary analyses did not reveal additional correlations. Our results suggest that in a cohort of CIS and MS patients, CSF ASYN levels are decreased, thus providing another possible link between MS and neurodegeneration. Future studies will need to be performed to confirm and extend these findings, to lead to a fuller understanding of the possible biological link between ASYN and MS. Alpha-synuclein levels in the Cerebrosinal Fluid (CSF) may reflect neurodegenerative processes. Here we measure CSF alpha-synuclein in demyelinating conditions ranging from Clinically Isolated Syndrome to Primary Progressive Multiple Sclerosis (MS). We find a similar magnitude of decreased alpha-synuclein compared to a control group in all such MS spectrum conditions; such a decrease may reflect an underlying early neurodegenerative disease process.
authors.affiliation: Second Department of Neurology, Hospital «Attikon», University of Athens Medical School, Haidari, Greece.
authors.forename: Roubina Ch
authors.initials: RCh
authors.lastname: Antonelou
authors.affiliation: Center for Neuroscience, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
authors.forename: Evangelia
authors.initials: E
authors.lastname: Emmanouilidou
authors.affiliation: Second Department of Neurology, Hospital «Attikon», University of Athens Medical School, Haidari, Greece.
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Gasparinatos
authors.affiliation: Center for Neuroscience, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
authors.forename: Theodora
authors.initials: T
authors.lastname: Velona
authors.affiliation: Second Department of Neurology, Hospital «Attikon», University of Athens Medical School, Haidari, Greece.
authors.forename: Konstantinos I
authors.initials: KI
authors.lastname: Voumvourakis
authors.affiliation: Second Department of Neurology, Hospital «Attikon», University of Athens Medical School, Haidari, Greece.|Center for Neuroscience, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
authors.forename: Leonidas
authors.initials: L
authors.lastname: Stefanis
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003711:Demyelinating Diseases / Q000134:cerebrospinal fluid* / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid* / Q000175:diagnosis*; D051844:alpha-Synuclein / Q000134:cerebrospinal fluid*
chemical_list: D015415:Biomarkers; D051844:alpha-Synuclein
keywords: CSF; ELISA; alpha-synuclein; multiple sclerosis; neurodegeneration